Endocrine System Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Endocrine-disrupting chemicals: an Endocrine Society scientific statement.
Vitamin D and human health: lessons from vitamin D receptor null mice.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials with recent milestones (3 completed or reporting results).
Clinical MilestonesViewHide
- 2026-07-07A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone DeficiencyResults posted
- 2025-09-26A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or BothResults posted
- 2026-01-30Locomotor Training With Testosterone to Promote Bone and Muscle HealthPrimary completion
- 2026-01-08PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismCompleted
- 2025-09-30A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerPrimary completion
- 2026-07-07ClinicalA Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone DeficiencyResults posted
- 2026-01-30ClinicalLocomotor Training With Testosterone to Promote Bone and Muscle HealthPrimary completion
- 2026-01-08ClinicalPaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismCompleted
- 2025-09-30ClinicalA Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerPrimary completion
- 2025-09-26ClinicalA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or BothResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes1
- Mice, Knockout1
Leading journals2
- Endocrine reviews2
- Environmental health and preventive medicine1
Leading researchers8
- Behlen JC1
- Bouillon R1
- Bourguignon JP1
- Carmeliet G1
- Chen J1
- Demay M1
- Diamanti-Kandarakis E1
- Giudice LC1
Affiliations (unnormalised)3
- Katholieke Universiteit Leuven1
- Laiko Hospital1
- Texas A&M University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.